The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals REGN and Sanofi’s SNY lead drug candidate Dupixent (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
The regulatory approval was supported by data readout from Phase 3 trial evaluating Dupixent, that met both primary and all secondary endpoints.
George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer, commented : “Young children with moderate-to-severe atopic dermatitis are a significantly underserved population of patients, who spend vulnerable years of their lives suffering through the relentless and far-reaching effects of this chronic disease. Dupixent has changed the atopic dermatitis treatment paradigm, significantly clearing skin and reducing itch, by targeting an underlying cause of this disease without broadly suppressing the immune system.”
FDA evaluated Dupixent’s supplemental Biologics License Applications (sBLA) under Priority Review, reserved for medicines that represent potentially significant improvements in efficacy or safety in treating serious conditions.
The company said that Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy through adulthood.
Regeneron Shares closed Tuesday’s trading session high at $613.98.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.